Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,626.00
Bid: 1,625.50
Ask: 1,626.00
Change: -140.50 (-7.95%)
Spread: 0.50 (0.031%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

Wed, 01st May 2024 07:46

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

The Fed announces its latest interest rate decision at 1900 BST. It is expected to keep rates on hold this week, with Chair Jerome Powell likely to say that the central bank is not yet confident enough to cut as inflation remains lofty.

Powell is expected to sound hawkish in a subsequent press conference following the decision.

"With the markets so bearishly positioned, there's a chance stocks could surge higher on Wednesday if the Fed sticks to their steady state, more so if investors are prepared to engage in a 'buy-the-fact' dynamic when Powell takes centre stage," SPI Asset Management analyst Stephen Innes commented.

"While risks around the Fed's mandate may appear more balanced now compared to the peak of the inflation scare, recent core price growth readings emphasize that inflation remains a primary concern, overshadowing worries about other economic indicators, so there is room for hawks to fly."

In early UK corporate news, GSK lifted its outlook, while Haleon affirmed guidance. Next said its first-quarter went better than planned, but expects a "weaker" second-quarter.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up slightly at 8,146.13

----------

Hang Seng: financial markets in Hong Kong closed

Nikkei 225: down 0.3% at 38,274.05

S&P/ASX 200: down 1.2% at 7,569.90

----------

Dow: closed down 570.17 points, 1.5%, at 37,815.92

S&P 500: closed down 1.6% at 5,035.69

Nasdaq Composite: closed down 2.0% at 15,657.82

----------

EUR: down at USD1.0657 (USD1.0690)

GBP: down at USD1.2479 (USD1.2523)

USD: up at JPY157.87 (JPY157.44)

GOLD: down at USD2,288.56 per ounce (USD2,298.10)

(Brent): down at USD85.48 a barrel (USD86.42)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

China - Labor Day. Financial markets closed.

France - Labor Day. Financial markets closed.

Germany - Labor Day. Financial markets closed.

Ireland - Labor Day. Financial markets closed.

Italy - Labor Day. Financial markets closed.

Spain - Labor Day. Financial markets closed.

Switzerland - Labor Day. Financial markets closed.

09:30 BST UK manufacturing PMI

11:00 BST Ireland unemployment

13:15 BST US ADP jobs report

14:45 BST US manufacturing PMI

15:00 BST US ISM manufacturing PMI

15:00 BST US job openings and labour turnover survey

19:00 BST US interest rate decision

----------

UK house price growth slowed last month, numbers from Nationwide showed. UK house prices rose 0.6% on-year in April, easing from a 1.6% surge in March. On a monthly basis, they fell 0.4%. They had declined 0.2% in March from February. "UK house prices fell by 0.4% in April, after taking account of seasonal effects. This resulted in a slowing in the annual rate of house price growth to 0.6% in April, from 1.6% the previous month," Nationwide analyst Robert Gardner said. "The slowdown likely reflects ongoing affordability pressures, with longer term interest rates rising in recent months, reversing the steep fall seen around the turn of the year. House prices are now around 4% below the all-time highs recorded in the summer of 2022, after taking account of seasonal effects."

----------

Politicians and canvassers are beginning their final day of campaigning ahead of Thursday's local elections in the UK. Voters in England and Wales will go to the polls on May 2 for local, mayoral, and police and crime commissioner elections. The polls are the final test of public opinion at the ballot box ahead of the next general election, which Prime Minister Rishi Sunak has said will come in the second half of 2024. Forecasts suggest the elections could see the Conservatives lose up to half of the council seats they are defending across 107 councils, having lost a third of seats last year. Most of the seats up for re-election were last contested in 2021, at the peak of Boris Johnson's popularity as the Covid-19 vaccine was rolled out. A total of 11 mayoral contests are also taking place, including for the London mayoralty. A wave of defeats for Sunak could be enough to push more Tory MPs into seeking to replace him as leader before the general election, though all counts will not be declared until Sunday, May 5.

----------

BROKER RATING CHANGES

----------

Berenberg raises FirstGroup price target to 195 (191) pence - 'buy'

----------

Berenberg raises HSBC price target to 830 (800) pence - 'buy'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said it expects annual sales to rise at the upper end of its forecast, following a "strong" start to 2024. GSK said revenue in the first-quarter of the year rose 5.9% to GBP7.36 billion from GBP6.95 billion a year prior. Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion. GSK reported 'other' expenses worth GBP533 million, hurting its bottom line, and swing from GBP297 million in gains a year prior. Chief Executive Officer Emma Walmsley said: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024." GSK now expects annual revenue to rise at the upper part of its 5% to 7% range, at constant currency. It expects constant currency operating profit growth in its core operations of 9% to 11%, its outlook raised from 7% to 10%. Core earnings per share growth of 8% to 10% at constant currency is now expected, the guidance bumped up from 6% to 9%.

----------

Haleon, a consumer health arm spun out of GSK, backed its annual guidance and reported a "solid" quarter. Reported revenue declined 2.2% on-year to GBP2.92 billion in the first-quarter of the year. Revenue rose 3.0% on an organic basis, however. Pretax profit grew 8.9% to GBP590 million from GBP542 million. Looking ahead, it still predicts annual organic revenue growth in the 4% to 6% range. CEO Brian McNamara said: "First quarter trading was solid and in line with guidance shared when we reported FY 2023 results. Organic revenue growth of 3.0% was impacted by lapping tough comparatives in the prior year particularly in respiratory health and pain relief." The CEO added: "Regionally, whilst growth was held back in the US from inventory adjustments by some retailers, Haleon's consumption in this region was strong, up mid-single digit and ahead of the market. As such, we remain confident of delivering on our FY guidance."

----------

Retailer Next said sales in recent weeks have been ahead of expectations, and it maintained its annual profit forecast. In the 13 weeks to April 27, its first-quarter, full price sales rose 5.7% on-year. The outcome was ahead of guidance, with the clothing and homewares seller having predicted growth of 5%. It still expects pretax profit to grow 4.6% in the full-year to GBP960 million. Next added: "We are maintaining our guidance for full price sales in the first half to be up 2.5%. This implies that our sales in Q2 will be down -0.3%. We expect the sales performance in the second quarter to be weaker than the first quarter because last year benefited from particularly warm weather from late May through to the end of June."

----------

COMPANIES - FTSE 250

----------

Aston Martin Lagonda recorded weaker results, for a first-quarter that it labelled a "period of transition". The carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened to GBP138.8 million from GBP74.2 million. Executive Chair Lawrence Stroll commented: "2024 is a year of immense product transformation at Aston Martin, with the introduction of four new models to the market before the end of the year. Our first quarter performance reflects this expected period of transition, as we ceased production and delivery of our outgoing core models ahead of the ramp up in production of the new Vantage, upgraded DBX707 and our upcoming V12 flagship sports car which we've confirmed today. As part of our ongoing programme of ultra-exclusive models, we will deliver a new Special in the fourth quarter of the year." It expects a second-quarter performance to be "broadly similar" to the first. Stroll added: "In March, we were pleased to successfully complete our planned refinancing, securing improved terms on new five-year senior secured notes. This followed upgrades from leading credit agencies, recognising the significant progress made by Aston Martin over recent years and the opportunity for our strategy to continue to deliver improved performance in the years to come. This, along with our existing lenders demonstrating their continued support through a 70% increase in the new [revolving credit facility] to GBP170 million, marked a significant step in strengthening our balance sheet, aligning Aston Martin for a positive financial future." Net debt as of March 31 stood at GBP1.04 billion, rising 20% from GBP868.1 million a year prior.

----------

Computacenter said its first-quarter went largely in line with expectations, though it noted a "challenging" period in the UK. The technology and IT service provider expects adjusted pretax profit in the first-half to be weaker than the prior year's GBP121.8 million. Computacenter said: "Computacenter expects to make further progress in 2024 with the performance for the group during the first quarter broadly in line with our expectations. Germany and North America delivered solid underlying performances while the UK remained challenging."

----------

OTHER COMPANIES

----------

Luxury brand Mulberry expects to report an annual revenue decline, as it grappled with a "backdrop of challenging macro-economic conditions". Group revenue for the year ended March 30 fell 4%, or 2.7% at constant currency, it said. "While we achieved positive revenue growth in the first half, Mulberry has not been immune to the broader downturn in luxury spending experienced in recent months, particularly in the UK and Asia. This decline was partially offset by positive trading in the US, where we have benefitted from increased brand awareness," CEO Thierry Andretta said. "Looking ahead, the trading environment in the UK and China remains challenging and we do not expect this to change in the short term. We are therefore managing the business prudently, focusing on executing our strategy and vision to become a global sustainable luxury brand."

----------

Renold won a GBP10.6 million deal to produce flexible couplings for the Royal Canadian Navy. "This contract, together with other military work recently awarded, means that Renold's military order book has increased by GBP13.1 million, over recent months," the supplier of industrial chains and related power transmission products said. Renold explained the new pact with be delivered over the next six years. Flexible couplings are a key component on a ship's propulsion system, the firm said.

----------

Touchstone Exploration said it has struck an all-share deal to acquire Trinity Exploration & Production. The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale". It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production." As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity Shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
Today 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
Today 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
Today 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
Today 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
Today 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
24 May 2024 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.